Instruction for use: M-M-R II

Dosage form: Lyophilizate for the preparation of a suspension

Active substance: Vaccinum ad prophylaxim morbillorum, rubeolae, parotitidis

ATX

J07BD52 Measles virus in combination with mumps and rubella viruses, live attenuated

Pharmacological group

Vaccines, serums, phages and toxoids

Nosological classification (ICD-10)

B05 Measles: Koplik Spots; Koryvyaya rash on the mucous cheek

B06 Rubella [German measles]: German measles; Rubella; Epidemic rubella

B26 Epidemic parotitis: Parotitis; Infectious parotitis (mumps)

Composition and release form

1 dose of polivakcina (0.5 ml) for SC administration contains 3 types of virus (measles, mumps and rubella virus), and neomycin about 25 μg, in single-dose vials complete with a solvent (vial or syringe); In the box 1 set or in boxes containing 10 single-dose vials and 10 bottles with a solvent.

Characteristic

Live vaccine against measles, mumps and rubella. A sterile lyophilized preparation contains ATTENUVAX (live measles virus vaccine), a measles virus with a lower virulence, derived from an attenuated Edmonston strain and grown in a chick embryo cell culture; MUMPSVAX (live vaccine against mumps virus), maternal parotitis strain Jeryl Lynn grown in chicken embryo culture and MERUVAX II (live rubella virus vaccine), Wistar RA 27/3 strain of live attenuated rubella virus grown in human diploid cell culture.

Pharmachologic effect

Mode of action - Immunostimulating.

Forms specific immunity to measles, mumps and rubella viruses.

Indications of the M-M-R II

Specific immunoprophylaxis of measles, mumps and rubella.

Contraindications

Diseases of the respiratory system or any infection accompanied by fever, active tuberculosis, blood disease, leukemia, lymphoma, etc. Malignancies affecting the bone marrow and / or lymphatic system, anaphylactic or anaphylactoid reactions in egg white, neomycin, primary and acquired immunodeficiency (AIDS or the like. clinical manifestations of infection with human immunodeficiency virus), impaired cellular immunity, or hypogammaglobulinemia dysgammaglobulinemia, the presence of congenital or hereditary immunodeficiencies the patient's relatives.

Application of pregnancy and breastfeeding

Contraindicated.

Side effects

Fever (38.3 ° C or more), malaise, mumps, nausea, vomiting, diarrhea, regional lymphadenopathy, thrombocytopenia, purpura, arthralgia and / or arthritis, myalgia, convulsions, incl. Febrile in children, headache, dizziness, paresthesia, optic neuritis, polyneuritis, Guillain-Barre syndrome, ataxia, paralysis of the eye nerves, otitis media, conjunctivitis, orchitis, erythema multiforme, rash, urticaria, anaphylactic and anaphylactoid reactions; At the injection site - transient burning and / or soreness, hyperemia, densification.

Dosing and Administration

SC, 0.5 ml, preferably in the outer part of the shoulder.

Precautionary measures

Don’t enter IV and IM. With special caution appoint if there is a history (including close relatives) of seizures, brain damage and other conditions in which it is necessary to avoid the stress associated with fever. It is necessary to exclude contact with diseases against which immunization was carried out. It is not recommended to vaccinate before 3 months after the transfusion of blood or plasma, the introduction of human immunoglobulin.

Storage conditions of the drug M-M-R II

In the dark place at a temperature of 2-8 ° C. Solvent - in the refrigerator or separately at room temperature

Keep out of the reach of children.

The shelf life of the drug M-M-R II

Lyophilizate for the preparation of solution for injection 0.5 ml / dose - 3 years. 5 years solvent

Lyophilizate for solution for injection -

Do not use beyond the expiration date printed on the package.